Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
135 hedge funds and large institutions have $663M invested in Merrimack Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 55 increasing their positions, 43 reducing their positions, and 26 closing their positions.
67% more call options, than puts
Call options by funds: $4.05M | Put options by funds: $2.43M
28% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 43
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 150 → 135 (-15)
29% less capital invested
Capital invested by funds: $931M → $663M (-$269M)
54% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$16.9M |
| 2 |
TCIM
TIAA CREF Investment Management
New York
|
+$15.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.48M |
| 4 |
TA
Teachers Advisors
New York
|
+$4.65M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$4.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$14.9M |
| 2 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$5.84M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$4.33M |
| 4 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
-$4.06M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$3.26M |
MACK Hedge Fund Activity: Q3 2015 in Review
135 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q3 2015, worth a combined $663M — down 29% from $931M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of MACK and 12 opened new positions — a net loss of 14 holders — while 43 trimmed existing stakes and 55 added.
The largest buyer was Westfield Capital Management, adding an estimated $16.9M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $14.9M sold.
- 135 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q3 2015, down from 150 in Q2 2015.
- Funds reported $663M of Merrimack Pharmaceuticals, Inc. stock for Q3 2015, down 29% quarter-over-quarter.
- 12 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q3 2015 and 26 closed out, a net change of -14 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q3 2015 was Westfield Capital Management, an estimated $16.9M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q3 2015 was Balyasny Asset Management, an estimated $14.9M sold.
Based on aggregated 13F filings for Q3 2015.